Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02063113 | Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.(MYELOME-PA) | terminated | N/A | 48 | Nantes University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | terminated | Phase 2 | 2 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 |
| clinicaltrials |
| NCT01728259 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | terminated | Phase 1 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 2 | May 9, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT04161118 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma(TIGER-CTL019) | terminated | Phase 2 | 3 | University of CologneOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04775680 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 25 | Adagene (Suzhou) LimitedINDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | terminated | Early Phase 1 | 5 | Samus Therapeutics, Inc.INDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03411031 | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | terminated | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01899326 | Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | N/A | 10 | Albert Einstein College of MedicineOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04075721 | First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone | terminated | Phase 1 | 10 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT04635735 | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04602065 | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial | terminated | Phase 1 / Phase 2 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04521335 | Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma(Repurpose-1) | terminated | Phase 1 | 2 | University of UtahOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function(BRIDGE) | terminated | Phase 2 | 35 | Oncopeptides ABINDUSTRY | 3 | Mar 10, 2023 | clinicaltrials |
| NCT03445663 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma | terminated | Phase 1 | 27 | Xencor, Inc.INDUSTRY | 2 | Mar 7, 2023 | clinicaltrials |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) | terminated | Phase 1 | 3 | SecuraBioINDUSTRY | 2 | Feb 27, 2023 | clinicaltrials |
| NCT02807454 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma(FUSIONMM-003) | terminated | Phase 2 | 37 | CelgeneINDUSTRY | 9 | Feb 21, 2023 | clinicaltrials |
| NCT03123393 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 49 | Calithera Biosciences, IncINDUSTRY | 6 | Feb 8, 2023 | clinicaltrials |
| NCT03238651 | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) | terminated | Phase 1 | 17 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | terminated | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02077959 | Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | terminated | Phase 2 | 16 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT01838369 | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | terminated | Phase 2 | 4 | BioInvent International ABINDUSTRY | 1 | Jan 11, 2023 | clinicaltrials |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | terminated | Phase 1 / Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT00096460 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) | terminated | Phase 2 / Phase 3 | 30 | Medical College of WisconsinOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM(ANCHOR) | terminated | Phase 1 / Phase 2 | 56 | Oncopeptides ABINDUSTRY | 4 | Dec 19, 2022 | clinicaltrials |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | terminated | Phase 3 | 72 | Janssen Research & Development, LLCINDUSTRY | 20 | Dec 2, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 22 | AmgenINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 210 | AmgenINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL | terminated | Phase 3 | 59 | Elorac, Inc.INDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 6 | Hangzhou Zenshine Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | AkesoINDUSTRY | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant | terminated | Phase 1 | 6 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia(LABMI) | terminated | Phase 4 | 119 | University Hospital, AngersOTHER_GOV | 1 | Oct 3, 2022 | clinicaltrials |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | terminated | Phase 2 | 5 | Rush University Medical CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | terminated | Phase 1 | 2 | Codiak BioSciencesINDUSTRY | 1 | Sep 2, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 23, 2023source: clinicaltrials